Drug Delivery
Silo Pharma Announces Partnership With Global CRO for CNS Homing Peptide
Silo Pharma, Inc. recently announced it has entered into an agreement with WuXi AppTec (Hong Kong) Limited for a preclinical small animal study of SPU-16,…
NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02 for Patients Afflicted With Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate
NeOnc Technologies Holdings, Inc. has begun patient enrollment for the Phase 2 clinical trial of NEO100-02, the company’s first of two drug candidates proceeding through…
SCHOTT Pharma Introduces Nest Design With More Cavities for Prefillable Polymer Syringes
SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, developed a new nest design for prefillable polymer syringes, which holds a total…
FDA Approves Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata
Sun Pharmaceutical Industries Limited recently announced the US FDA approved LEQSELVI (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia areata. Alopecia…
IMUNON Announces 11.1 Month Increase in Overall Survival in Patients With Newly Diagnosed, Advanced Ovarian Cancer Treated With IMNN-001
IMUNON, Inc. recently announced positive topline results from the Phase 2 OVATION 2 Study with IMNN-001 in patients with advanced ovarian cancer. OVATION 2 is…
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug for Early Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. recently announced the first subject has been dosed with a subcutaneous formulation of sabirnetug (ACU193) in a Phase 1 pharmacokinetic (PK) comparison…
2024 Respiratory Drug Development eBook – CDMOs Will Become More Essential to Inhalation Device Programs
In this fifth annual Respiratory e-book, learn more about several companies and their contributions to inhalation drug delivery and device design.
WHITEPAPER - Versatility of Geleol™ Mono- and Diglycerides NF
Geleol exerts different functional roles, depending on the drug, formulation, and the process applied. It may serve as carrier and release modifier for oral formulations and plasticizer in tablet film coating processes. It may be combined with polymers and/or other non-digestible lipids like Compritol®….
Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients
Oragenics, Inc. recently announced it has developed a new formulation for its novel neurosteroid. Oragenics’ lead drug candidate for concussion, ONP-002, is a new chemical…
EnPlusOne Biosciences Reveals Breakthrough Enzymatic Synthesis of Leqvio Antisense Strand
EnPlusOne Biosciences, Inc. recently announced it had achieved the successful synthesis of the antisense strand of the commercially approved siRNA drug, Leqvio (inclisiran), a treatment…
Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
Zevra Therapeutics, Inc. recently announced the US FDA has indicated that it will convene a meeting with the recently formed Genetic Metabolic Diseases Advisory Committee…
Skinvisible Unveils Promising Data on Transdermal Obesity Formulations
Skinvisible Pharmaceuticals, Inc. recently announced exciting data demonstrating its transdermal delivery of obesity drugs (and other glucose-controlling drugs), including a GLP-1 agonist and CB-1 receptor…
MedPharm & Tergus Pharma Merger Forms Topical & Transepithelial CDMO Leader
MedPharm, Ltd., an Ampersand Capital Partners portfolio company, and Tergus Pharma, a Great Point Partners portfolio company, recently announced a merger. The combined topical and…
Silo Pharma Announces Exclusive Global License for Lead Candidate
Silo Pharma, Inc. recently announced it has entered into an exclusive, global license agreement with Columbia University to further develop, manufacture, and commercialize its lead…
IntelGenx Obtains Preliminary Efficacy Results for the BUENA Montelukast VersaFilm Phase 2a Clinical Trial in Patients With Mild to Moderate Alzheimer’s Disease
IntelGenx Corp. has successfully completed the BUENA Alzheimer’s disease (AD) study. The BUENA study was designed as a Phase 2a proof of concept study to…
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
Biora Therapeutics, Inc. recently shared positive topline results from its clinical trial of BT-600, an orally administered drug-device combination in development for the potential treatment…
WEBINAR - Development of Orally Delivered GLP-1 Therapeutics…From Diabetes to Obesity and Beyond
Join Quotient Sciences’ experts on July 18 as we explore the latest developments in orally-delivered GLP-1 agonists, the potential for these therapeutics and overcoming the manufacturing challenges.
NeOnc Technologies Completes $18.5-Million Financing, Advances Phase 2 Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status
NeOnc Technologies Holdings, Inc. has completed an $18.5-million financing to support the ongoing development and Phase 1 and 2 clinical studies of its novel drug…
Agile Therapeutics Announces Definitive Merger Agreement With Insud Pharma
Agile Therapeutics, Inc. recently announced it has entered into a definitive merger agreement with Insud Pharma, S.L. pursuant to which Insud, through its US subsidiary,…
Silo Pharma Partners With AmplifyBio to Advance SPC-15 for PTSD & Anxiety
Silo Pharma, Inc. recently announced it has awarded a contract to its contract research organization (CRO) partner AmplifyBio for an investigational new drug (IND)-enabling large…
What are Drug Delivery Systems?
Drug delivery systems are engineered technologies for the targeted delivery and/or controlled release of therapeutic agents. The practice of drug delivery has changed significantly in the past few decades and even greater changes are anticipated in the near future. Drug delivery includes but is not limited to oral delivery, gene/cell delivery, topical/transdermal delivery, inhalation deliver, parenteral delivery, respiratory delivery, capsules, particle design technology, buccal delivery, etc.
The Evolution of Drug Delivery Systems
Drug delivery systems have greatly evolved over the past 6 decades. In the past 12 years specifically, there have been huge advancements in drug delivery technology. For instance, advanced medication delivery systems, such as transdermal patches, are able to deliver a drug more selectively to a specific site, which frequently leads to easier, more accurate, and less dosing overall. Devices such as these can also lead to a drug absorption that is more consistent with the site and mechanism of action. There are other drug delivery systems used in both medical and homecare settings that were developed because of various patient needs and researchers continue to develop new methods.
Drug Delivery System Market Size
The pharmaceutical drug delivery market size is studied on the basis of route of administration, application, and region to provide a detailed assessment of the market. On the basis of route of administration, it is segmented into oral delivery, pulmonary delivery, injectable delivery, nasal delivery, ocular delivery, topical delivery, and others.
The estimated global market size of drug delivery products was $1.4 trillion in 2020. Unfortunately, 40% of marketed drugs and 90% of pipeline drugs (mostly small molecules) are poorly soluble in water, which makes parenteral, topical, and oral delivery difficult or impossible. In relation, poor solubility often leads to low drug efficacy. Add in the fact that many other hurdles exist in the form of drug loading, stability, controlled release, toxicity, and absorption – it’s not hard to understand the difficulties in bringing new drug products to market. Additionally, biopharmaceuticals (proteins, peptides, nucleic acids, etc) and combination drug products possess many of these same problematic obstacles that affect efficacy. These challenges, coupled with the complexity and diversity of new pharmaceuticals, have fueled the development of a novel drug delivery platforms that overcome a great many bioavailability and delivery obstacles. By leveraging these platforms, pharmaceutical and biopharmaceutical companies can improve dosing accuracy, efficacy, and reproducibility in their drug discovery and drug delivery research.
Drug Delivery System Demand
The demand for pharmaceutical products worldwide is only going to increase in the coming years, as old and emerging diseases continue to threaten the well-being of people globally. Drug discovery efforts are expected to intensify, generating a large variety of active compounds with vastly different structures and properties. However, it is well known that despite tremendous output of the drug discovery process, the success rate of a candidate compound becoming an approved drug product is extremely low. The majority of candidate compounds are discarded due to various hurdles in formulation and preclinical testing (such as issues with solubility, stability, manufacturing, storage, and bioavailability) before even entering into clinical studies. Therefore, advances in formulation and drug delivery, especially the development of new and versatile biomaterial platforms as effective excipients, may salvage many “difficult,” otherwise triaged, drug compounds, and significantly enhance their chance of becoming viable products. Furthermore, breakthroughs in biomaterial platform technologies will also facilitate life cycle management of existing APIs through reformulation, repurposing of existing APIs for new indications, and development of combination products consisting of multiple APIs.